The voluntary recall, originally initiated due to a product compliant in October 2018 for mislabeling, continues for anti-seizure drug, Levetiracetam injection in single-dose bags.
Dr Reddy’s Laboratories has been issued with a Form 483 after an inspection at its active pharmaceutical ingredient (API) plant in Miryalaguda in Telangana, India.
Dr. Reddy’s Laboratories Ltd has said it may invest in additional manufacturing capacity to support its efforts to grow in the European hospital drug market.
Dr Reddy’s has set out to build in the Japanese market days after revealing that higher generic and API sales elsewhere had been pegged back by currency fluctuations.
Dr. Reddy’s may not have as big a hill to climb as some observers suggest to regain customers lost as a result of the closure of its Mexican API plant, according to Barclays.
Dr Reddy's Laboratories has started first clinical trials of a
"four-in-one" polypill clinical trial, which could revolutionise
the cardiovascular drugs market.
ClinTec International and Dr. Reddy's Laboratories have announced a
partnership, in which both parties are to jointly develop an
anti-cancer drug that belongs to the topoisomerase inhibitors class
of compounds.
Dr. Reddy's Laboratories has announced the inauguration of its
seventh finished dosage plant in India, reflecting the country's
unprecedented growth as a generic pharmaceuticals manufacturer.
